Matching articles for "icatibant"

Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema

   
The Medical Letter on Drugs and Therapeutics • February 26, 2018;  (Issue 1541)
The FDA has approved Haegarda (CSL Bering), a human plasma-derived C1 esterase inhibitor (C1INH), for prophylaxis against hereditary angioedema (HAE) attacks in adolescents and adults. Haegarda is...
The FDA has approved Haegarda (CSL Bering), a human plasma-derived C1 esterase inhibitor (C1INH), for prophylaxis against hereditary angioedema (HAE) attacks in adolescents and adults. Haegarda is the fourth C1INH to be approved by the FDA and the second to be approved for HAE prophylaxis. Unlike the other C1INHs, Haegarda is self-administered subcutaneously rather than intravenously.
Med Lett Drugs Ther. 2018 Feb 26;60(1541):39-40 | Show Full IntroductionHide Full Introduction

A Recombinant C1 Esterase Inhibitor (Ruconest) for Hereditary Angioedema (online only)

   
The Medical Letter on Drugs and Therapeutics • March 28, 2016;  (Issue 1491)
The FDA has approved Ruconest (Salix), a recombinant analog of human complement component 1 esterase inhibitor (C1INH), for treatment of acute attacks in patients with hereditary angioedema...
The FDA has approved Ruconest (Salix), a recombinant analog of human complement component 1 esterase inhibitor (C1INH), for treatment of acute attacks in patients with hereditary angioedema (HAE).
Med Lett Drugs Ther. 2016 Mar 28;58(1491):e44-5 | Show Full IntroductionHide Full Introduction

In Brief: Icatibant (Firazyr) for Hereditary Angioedema

   
The Medical Letter on Drugs and Therapeutics • November 28, 2011;  (Issue 1378)
The FDA has approved icatibant (Firazyr – Shire), a selective bradykinin B2 receptor antagonist, for treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare autosomal dominant disorder...
The FDA has approved icatibant (Firazyr – Shire), a selective bradykinin B2 receptor antagonist, for treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare autosomal dominant disorder (estimated prevalence 1:10,000-50,000) in which patients experience recurrent and frequently unpredictable attacks of angioedema lasting 2-5 days, typically involving the extremities, gastrointestinal tract, genitalia, face, oropharynx or larynx. Laryngeal edema may be life-threatening. HAE is usually caused by a mutation of the C1-inhibitor (C1-INH) gene. C1-INH is a serine proteinase inhibitor that suppresses production of plasma kallikrein, which generates bradykinin. Bradykinin is a vasoactive substance that increases vascular permeability. Suppressing production of either kallikrein or bradykinin prevents uncontrolled vascular permeability and angioedema.

Icatibant is the third drug in the past 3 years approved for treatment of HAE. The other two are Berinert, a human plasma-derived C1 esterase inhibitor given intravenously (IV), and Kalbitor, a recombinant plasma protein kallikrein inhibitor given subcutaneously.1 Icatibant is the only one of the three that can be administered subcutaneously by the patient. A fourth drug, Cinryze, a C1 esterase inhibitor is approved for prophylaxis; it is given IV every 3 or 4 days.

In a double-blind randomized trial, clinically significant relief of acute HAE symptoms occurred earlier with icatibant than with tranexamic acid (2 hours vs. 12 hours). In another trial, icatibant was found to have a nonsignificant benefit (2.5 hours vs. 4.6 hours) compared to placebo.2 How it compares to the other 2 drugs approved for treatment of HAE remains to be determined.3 A single dose of icatabant costs $2427.864; patients who do not respond to the first dose can receive a second dose and, if necessary, a third, at 6-hours intervals.

1. Three new drugs for hereditary angioedema. Med Lett Drugs Ther 2010; 52:66.

2. M Cicardi et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363:532.

3. BP Morgan. Hereditary angioedema — therapies old and new. N Engl J Med 2010; 363:581.

4. Cost of a single dose according to most recent data (October 2011) from retail pharmacies nationwide available from Wolters Kluwer Health.

Download U.S. English
Med Lett Drugs Ther. 2011 Nov 28;53(1378):96 | Show Full IntroductionHide Full Introduction